Ora Pharm Launches NZ Grow Co. To Support Next Phase Of Medicinal Cannabis Sector

Ora Pharm today announced the launch of NZ Grow Co., a new grower collective designed to support the next phase of New Zealand’s medicinal cannabis industry and strengthen its position as a high-value export sector.

The launch aligns with the Government’s completion of the medicinal cannabis licensing regime review, announced today by Associate Health Minister David Seymour, and follows broader reforms signalling a more practical and enabling regulatory approach across the cannabis and hemp sectors.

NZ Grow Co. provides an integrated model linking cultivation, processing, and export capability. It enables growers to participate in regulated international markets through a coordinated system, rather than operating as standalone producers.

Ora Pharm Chief Executive Zoe Reece said the sector is now moving beyond its early, fragmented phase.

“Regulatory clarity is critical to unlocking investment and participation. What we are seeing now is the opportunity to build a more coordinated, export-focused industry that delivers real economic value.”

Ora Pharm currently works with approximately two-thirds of New Zealand’s licensed cannabis cultivators and has expanded its processing capability with a new extraction facility in North Waikato. Operations are GACP-compliant, with EU GMP certification underway - positioning the business to meet the standards required in regulated export markets.

Reece said the focus must now shift from establishment to execution.

“New Zealand has strong fundamentals - trusted primary production, a reputation for quality, and a stable regulatory environment. The next step is building the infrastructure and systems that allow the sector to scale and compete internationally.”

Executive Chair Stuart Wilcox said New Zealand’s opportunity lies in premium positioning.

“This is not a commodity play. With the right settings, New Zealand can build a high-quality, science-led export sector based on consistency, traceability, and compliance.”

Ora Pharm said continued progress in regulatory settings will be key to maintaining momentum, supporting grower participation, and attracting long-term investment.

© Scoop Media